IMARC Group

A new report from IMARC Group expects the volume share of generic drugs in the US Dyslipidemia market to reach levels worth more than 92% by 2016.

A new study from IMARC Group suggests that it will take around 4 to 5 years for the country’s skimmed milk powder production to reach levels that it had in 2008-09.

A new report from IMARC Group expects the future growth of the energy efficient lighting and modern display industries to be constrained by a critical supply shortage of Terbium and Europium.

Driven by an increasing prevalence of diabetes, the total market for Insulin and Non-Insulin Antidiabetics is expected to reach sales worth US$ 2803 Million by 2015.

A new report from IMARC Group expects that as a result of an avalanche of patent expiries and a thin pipeline, sales worth US$ 8.7 Billion will be eroded from the US cholesterol market.

With outsourcing trends in the global clinical trials market increasing rapidly, the demand of efficient cold chain logistic services is predicted to grow robustly in the coming years.

With 97% of the global production and 50% of the global reserves, China currently dominates the global rare earth elements market.

A new report from IMARC Group expects that driven by factors such as a strong pipeline and ability to treat diseases with high unmet needs, the global market for biopharmaceuticals is expected to reach revenues worth US$ 167 Billion by 2015.

A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.

Driven by a high shelf life and an increased convenience, the demand for UHT milk in India is expected to grow more than three folds during 2010-11 and 2016-17.